

---

# A Short Review on Circulating Micro-RNAs in Diabetic Patients

Carella Angelo Michele<sup>1\*</sup>, Marinelli Teresa<sup>1</sup>, Melfitano Armando<sup>1</sup>,  
Di Pumpo Michele<sup>1</sup>, Modola Giovanni<sup>1</sup>, De Luca Pasquale<sup>1</sup>  
and Benvenuto Angelo<sup>1</sup>

DOI: 10.9734/bpi/hmms/v15/10868D

---

## ABSTRACT

microRNAs (miRNAs) are short noncoding RNA sequences, approximately 20-22 nucleotides, synthesized in the cell nucleus, through a complex multi-step biosynthetic process, starting from RNA polymerase II. miRNAs regulate a wide range of biological processes as cell differentiation, proliferation and development, cell-to-cell communication, cell metabolism and apoptosis. There is evidence that miRNAs may have a role in molecular mechanisms linked to cellular pathways of certain diseases, as viral infections, cancer, diabetes and cardiovascular disease. miRNAs expression was investigated in diabetes mellitus: a lot of altered circulating levels of different miRNAs were found to be linked to type 1 and type 2 diabetes, both at onset and in advanced disease. At least 12 circulating miRNAs were found consistently dysregulated in type 1 diabetes mellitus and, more or less, 40 circulating miRNAs in type 2 diabetic patients. miR-126 seems to be miRNA most linked to pathways and development of type 1 and type 2 diabetes and their complications. Dysregulation of several miRNAs involves different aspects of diabetic disease: glycemic control, residual beta cell function, insulin secretion and sensitivity, micro- and macro-vascular complications, particularly endothelial dysfunction, renal disease and retinopathy. The analysis of circulating miRNAs might be a good source of diagnostic and prognostic biomarkers in diabetic patients. Large and long-term clinical studies should be conducted to evaluate the value of these nucleotides as biomarkers for predicting progression of diabetes, though the high detection costs might be the main limitations on their use in daily clinical practice.

*Keywords: Circulating microRNA; diabetes mellitus.*

## 1. INTRODUCTION

microRNAs (miRNAs) are a large family of short noncoding RNA sequences [1] which modulate gene expression and regulate a wide range of biological cell processes, including cell growth and proliferation, differentiation, organogenesis, metabolism, stress response, and tissue remodeling [2]. It has been estimated that the human genome contains more than 2500 mature miRNAs [1,2] and they could regulate 74-92% of all protein-encoding mRNAs in a tissue- and or cell-specific manner [3].

There is evidence that miRNAs may have a role in molecular mechanisms linked to cellular pathways of certain diseases, as viral infections, cancer, Alzheimer's, diabetes and cardiovascular disease [2,4-8].

miRNAs are detectable in plasma, urine, cerebrospinal and other extracellular fluids, where they are carried within small membrane vesicles, exosomes, in the form of high-density lipoprotein complexes, or complexed to carrier proteins, known as argonaute-2 proteins [9-11]. The presence of circulating endogenous miRNAs makes sure that they may be identified, measured and used as potential disease biomarkers [6,7].

---

<sup>1</sup>Department of Internal Medicine, "T. Masselli-Mascia" Hospital, San Severo, Italy.

\*Corresponding author: E-mail: mic.carella@virgilio.it;

Several techniques are available for quantifying circulating miRNAs, such as quantitative real-time Polymerase Chain Reaction (qRT-PCR) [12], Northern blotting [13], bead-based flow Cytometry [14], Microarray [15] or Deep sequencing [16]. In several studies the potential role of different miRNAs in cardiovascular diseases has been widely proved [17-21] and other studies have investigated a possible role of circulating miRNAs as biomarkers for atherosclerotic disease [22-24]; in the past few years, a potential link between miRNAs expression and diabetes mellitus was also recognized by means in vitro, in vivo and in clinical studies [25].

Detection of miRNAs expression can be implicated in physiological or pathological changes and it can even be useful for the prognosis or diagnosis of the onset and progression of diseases.

### **1.1 Aim of the Study**

The purpose of the present review was to examine the latest evidences on potential links between circulating miRNAs and diabetic disease, as well as to evaluate whether the detection of these nucleotides in the bloodstream can play a role in daily clinical practice.

## **2. MATERIALS AND METHODS**

A review of recent literature has been carried out via Pub Med database, using these search terms: circulating microRNA and diabetes mellitus. Search was not limited by language or human subjects. All the found items, published in the last three years, from January 2015 to December 2017, were analysed. Additional articles were selected from the bibliographies of the quoted references.

## **3. RESULTS**

60 items were obtained and article types were determined using filters available on Pub Med database; 2 items were editorials and 58 journal articles, including 8 reviews (2 systematic reviews), 3 clinical studies/trials (1 randomized controlled trial), 1 comparative study, 1 meta-analysis, 3 comments; 14 items were related to animal models. Guidelines were not found, neither consensus nor observational studies nor case report; the remaining items were prevalently other journal articles or other publication types. Other data were deduced from retrospective analysis and by careful assessment of the obtained items and their references. Most of the data are provided by laboratory research rather than by clinical data; our research has provided only four clinical studies enrolling a small number of patients. The analysis of obtained data showed that a lot of altered circulating levels of different miRNAs were found to be linked to type 1 and type 2 diabetes, both at onset and in advanced disease.

Dysregulation of several miRNAs involves different aspects of diabetic disease: glycemic control, residual beta cell function, insulin secretion and sensitivity, micro- and macro-vascular complications, particularly endothelial dysfunction, renal disease and retinopathy.

At least 12 circulating miRNAs were found consistently dysregulated in type 1 diabetes mellitus: miR-21-5p, miR-24-3p, miR-100-5p, miR-126, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-210-5p, miR-342-3p, miR-375 and miR-1275; these miRNAs were involved in pathways related to immune system and adaptive immune response, cell survival, cell proliferation and insulin biosynthesis and secretion.

On the other hand, more or less 40 circulating miRNAs emerge significantly dysregulated in type 2 diabetes; particularly miR-7, miR-14q32, miR-21, miR-29a, miR-92a, miR-122, miR-126, miR-130b, miR-155 and miR-192 are potential circulating biomarkers of type 2 diabetes. miR-126 seems to be miRNA most linked to pathways and development of type 1 and type 2 diabetes and their complications.

## **4. DISCUSSION**

Increasing evidence suggests a potential relevant role of circulating miRNAs as novel diagnostic and prognostic biomarkers for diabetes, assuming their implications in the pathogenesis of this disease, so

much that miRNAs might contribute to a better understanding of the mechanisms involved in diabetes and its complications. In this regard, we have found several evidence for both type 1 and type 2 diabetes.

#### **4.1 miRNAs in Type 1 Diabetic Patients**

There is evidence that the levels of several miRNAs were found deregulated in plasma and urine from patients with diagnosed type 1 diabetes compared to age-matched controls [26].

miR-21, miR-126, and miR-210 resulted significantly deregulated in a cohort study carried out among clinical pediatric type 1 diabetic patients with duration of disease longer than 1 year. More in detail, urinary miR-126 levels in diabetics were significantly lower than in age- and gender-matched controls and there was a significant correlation between patients' glycosylated hemoglobin mean and urinary miR-126 concentration, whereas no significant difference for miR-126 plasma levels was found between diabetics and control group; moreover, in diabetic patients, a significant correlation between inflammatory C-reactive protein values and urinary miR-21 concentration was found. A significant increase of miR-21 and miR-210 was also observed both in the plasma and urine of diabetic patients [27].

Since miR-126 was found to be expressed in glomerular and peritubular endothelial cells [28], and decreased levels of miR-126 are associated with reduced response to vascular endothelial growth factor and endothelial dysfunction [29,30], deregulation of miR-126 could indicate a potential local endothelial dysfunction in the kidney of type 1 diabetic children. In the EURODIAB Prospective Complications Study, miR-126 levels emerged significantly lower in type 1 diabetic patients and were associated with proliferative retinopathy [31].

miR-21 is known to induce fibrosis in many organs including heart [32] and kidney [33] and promotes Transforming growth factor- $\beta$ -mediated effects on endothelial dysfunction [34], therefore miR-21 levels in plasma and urine of young type 1 diabetic patients might serve as a potential noninvasive biomarker to identify patients with a high risk for ongoing endothelial dysfunction or future kidney and cardiovascular injuries. There is evidence that miR-210 is modulated by hypoxia and high glucose in cardiomyocytes and endothelial cells cultured in vitro [35]; it is not surprising that upregulation of this miRNA leads to mitochondrial dysfunction and oxidative stress, potential determinants of ischemic heart failure [36]. In conclusion, these findings, that need to be validated in future large-cohort prospective studies, show that a dysregulation of circulating miR-21, miR-126, and miR-210 might indicate an early onset of diabetes-related cardiovascular diseases.

Another miRNA, for which a potential link with type 1 diabetes has been hypothesized, is miR-375; in vitro studies have shown that this miRNA is involved in pancreatic islet cell development [37], inhibits insulin gene expression in response to glucose [38], and regulates voltage-gated Na<sup>+</sup> channels and the exocytotic machinery [39]. As miR-375 is highly expressed in the endocrine pancreas, it has been postulated that its circulating level might reflect beta cell alterations and might be altered in the blood of type 1 diabetics recently diagnosed. Serum levels of miR-375 were found lower in type 1 diabetic children versus age-matched controls, without any correlations with glycosylated hemoglobin, glycemia, and number of autoantibodies [40]. Circulating levels of this miRNA might be proposed as a biomarker to detect pancreatic beta cell death, maintenance of normal insulin synthesis and secretion and to predict the development of type 1 diabetes mellitus.

An association with improved glycemic control and better residual beta cell function has also been found for miR-25, suggesting that circulating levels of this miRNA could be used during early and intensive management of newly diagnosed diabetes, to improve blood glucose control and reduce microvascular complications [41].

In a cohort of 123 children with new-onset type 1 diabetes mellitus, the miRNA hsa-miR-197-3p was found as strong predictor of residual beta cell function, 1 year after diagnosis in type 1 diabetic children [42].

Lastly, it has been postulated that several miRNAs, as miR-14q32, miR-24-3p, miR-100-5p, miR-146a-5p, miR-148a-3p, miR-150-5p, miR-181a-5p, miR-342-3p, miR-375 and miR-1275, have a recognized role in the immune system and significantly modulate several miRNAs expression of the major type 1 diabetes autoantigens, suggesting that these miRNAs may be involved in the development of autoimmunity and inflammation in diabetic patients [26,43,44].

## **4.2 miRNAs in Type 2 Diabetic Patients**

Circulating miRNAs expression was also investigated in type 2 diabetes mellitus.

miR-126 was found to be one of miRNAs most linked to the development of diabetes and its complications. In susceptible individuals, decreased levels of miR-126 in peripheral blood were found already before the clinical manifestation of type 2 diabetes [45], whereby miR-126 has been proposed as a predictor of type 2 diabetes onset [46]. Moreover, because reduced levels of miR-126 were found in type 2 diabetics and in patients with coronary artery disease [47], miR-126 might also serve as a biomarker for predicting diabetic myocardial ischemia. The endothelial cell-derived miR-126 is also one of the identified downregulated miRNAs in atherosclerotic disease and it was found most consistently associated with type 2 diabetes [48]; actually, since miR-126 has been shown to play an important role in maintaining endothelial cell homeostasis and vascular integrity [29,30], it has been suggested that this unique plasma miRNA might become a valuable tool to predict micro- and macrovascular complications of diabetes.

In truth, apart from miR-126, other miRNAs as miR-92a, miR-145, miR-155 and miR-17, are also abundantly expressed in the vessel wall, in endothelial cells, in vascular smooth muscle cells and in inflammatory cells of patients with atherosclerotic disease [22]. Other findings have shown that miR-126, but also miR-92a, miR-155, miR-14q32 and others, might play a determinant role in several processes involving regulation of lipid biosynthesis, lipoprotein metabolism, immune responses, and vascular remodeling including maladaptive processes of atherosclerosis, vascular restenosis and aneurysm formation [23,24]. At last but not least, there is evidence that miR-126 exhibits also antithrombotic properties via regulating post-transcriptional tissue factor expression. In a recent study, low miR-126 levels were found to be associated with markedly increased vascular inflammation, as evident from the levels of vascular adhesion molecule-1 and fibrinogen as well as leukocyte counts. With optimization of the anti-diabetic treatment miR-126 levels increased and thrombogenicity was reduced [49]; therefore the detection of circulating miR-126 might be also useful for follow-up, to evaluate therapeutic response and glycemic control.

There is evidence that circulating miR-122 is associated with prevalent insulin resistance, obesity, metabolic syndrome, type 2 diabetes, and an adverse lipid profile. Circulating miR-122 levels are elevated in people with prevalent metabolic syndrome or type 2 diabetes; moreover elevated serum levels of miR-122 antedate the manifestation of metabolic syndrome and type 2 diabetes, so that miR-122 might be associated with future development of metabolic syndrome and type 2 diabetes in the general population [50].

Plasma levels of miR-7 were found significantly elevated in type 2 diabetics and significantly associated with microvascular complications [51], whereas serum miR-130b levels were found significantly decreased in type 2 diabetic patients and further decreased in diabetics with nephropathy [52]; circulating miR-130b might be proposed as new biomarker for early diagnosis of diabetic nephropathy. miR-130b may possibly be involved in the pathological mechanism of diabetic nephropathy, such as lipid metabolic disorders, oxidative stress, extracellular matrix deposition and renal fibrosis.

The results of a recent Taiwanese study, carried out in type 2 diabetic patients, have shown that miR-21 level is more significantly increased in patients with overt proteinuria and microalbuminuria than in patients without diabetic nephropathy; whereas miR-29a level is up-regulated in subjects with more progressive diabetic nephropathy compared with normoalbuminuric patients. Moreover, although no significant difference was observed in circulating levels of miR-192 between diabetics with and without diabetic nephropathy, circulating levels of miR-192 were different between microalbuminuria and overt

proteinuria groups, suggesting that miR-192 levels might be a potential marker for late diabetic nephropathy progression [53].

### **4.3 Updating Versus Previous Data**

In this extension of our previous work [54], we tried to quickly update the previously obtained data by extending our Pub Med search from January 2018 to December 2020, leaving the search terms unchanged: circulating microRNA and diabetes mellitus. We found 129 other items that confirmed the correlation between some circulating miRNAs and diabetes mellitus. In the last 3 years, other miRNAs have been identified through clinical and research studies in both type 1 and type 2 diabetic patients. Circulating miR-192 [55] and miR-21 [56] were confirmed as potential biomarker for risk of type 2 diabetes in human and in animal, but also new circulating miRNAs, as miR-194 [55], miR-135 [57], miR-486, miR-15b, miR-146b [58], miR-146a [59,60] and others [59], have been identified as potential predictors of type 2 diabetes future risk.

Several new miRNAs have also been identified for their correlation with type 1 diabetes [61-63]; in particular, increased expression of circulating miR-101-3p was found highly expressed in pancreatic  $\beta$  cells of type 1 diabetics and it might play a role in the pathogenesis of type 1 diabetes by multiple molecular pathways [64].

Other miRNAs were identified as potential biomarkers for early diagnosis of gestational diabetes and its complications [65-68] and it has been confirmed that several new miRNAs may have a role in the pathogenesis of vascular diabetic complications as coronary artery disease (miR-126, miR-210, miR-130, miR-30c, miR-92a, miR-204) [69-73] and acute ischemic stroke (miR-195-5p, miR-451a) [74], nephropathy (miR-196-3p, miR-203, miR-154-5p, miR-155) [75-78], retinopathy (miR-15a, miR-15b, miR-1281, miR-3197, miR-2116-5p) [79-82] and limb ischemia (miR-4739, miR-21/PDCD4, miR-323b-5p) [83-86].

Finally, human and animal studies have highlighted potential relationships between circulating levels of some miRNAs and several dysmetabolic complications of diabetes [87-90].

### **4.4 Current Limits and Future Perspectives**

Analysis and detection of circulating miRNAs might be a good source of diagnostic and prognostic biomarkers in diabetic patients, as well as potential interesting therapeutic targets for the development of novel treatments, due to their regulatory role on gene networks controlling different crucial aspects of metabolism, including lipid and glucose homeostasis [91]. Circulating miRNAs might be ideal biomarkers because they are stable and resistant to degradation by ribonucleases and may be easily detected in the bloodstream by highly sensitive and specific quantitative assay [7].

Several techniques are available for quantifying circulating miRNAs, such as quantitative real-time Polymerase Chain Reaction (qRT-PCR) [12], Northern blotting [13], bead-based flow Cytometry [14], Microarray [15] or Deep sequencing [16]; of these assays, qRT-PCR seems superior because of its high sensitivity, specificity and reproducibility.

Unfortunately, the current methods used for miRNAs detection usually require high costs and this aspect exerts limits on their use in daily clinical practice; in this way, research should try to overcome this limiting factor by developing less expensive detection techniques whereas spending review and cost-containment measures in health care represent a significant management problem. Another limit on use of miRNAs in daily clinical practice might be the lack of availability of long-term and comparative clinical trials; larger longitudinal clinical studies with large sample size and with standardized system for the analysis of miRNAs should be conducted to confirm the clinical value of these nucleotides as biomarkers of diabetic disease.

## **5. CONCLUSION**

The potential role of circulating miRNAs as stable blood-based biomarkers for early detection, follow-up and treatment of diabetes and its complications is promising. There are currently no circulating

miRNAs that are validated as biomarkers of diabetic disease for use in routine clinical practice; the lack of evidence from significant clinical studies in both type 1 and type 2 diabetic patients as well as high detection costs are the main limitations to the use of these nucleotides in daily clinical practice.

In the past few years we have registered a growing interest of Researchers in these new biomarkers that might represent a valuable tool also in the field of diabetes. In the next future, larger and long-term randomized controlled trials must be undertaken; comparative clinical studies, between circulating miRNAs and biomarkers commonly employed for management of diabetics in daily clinical practice, are also desirable. Particularly, new low-cost and wide availability assays to detect specific biomarkers with high sensitivity and specificity need to improve early diagnosis and follow-up as well as to predict disease progression, complications and therapeutic response in diabetic patients.

## COMPETING INTERESTS

Authors have declared that no competing interests exist.

## REFERENCES

1. Ha M, Kim VN. Regulation of microRNA biogenesis. *Nat Rev Mol Cell Biol.* 2014;15(8):509-524. Available:<https://doi.org/10.1038/nrm3838>
2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell.* 2004;116(2):281-297. Available:[https://doi.org/10.1016/S0092-8674\(04\)00045-5](https://doi.org/10.1016/S0092-8674(04)00045-5)
3. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, et al. A pattern-based method for the identification of microRNA binding sites and their corresponding hetero duplexes. *Cell.* 2006;126(6):1203-1217. DOI: 10.1016/j.cell.2006.07.031
4. Bushati N, Cohen SM. microRNA functions. *Annu Rev Cell Dev Biol.* 2007;23:175-205. Available:<https://doi.org/10.1146/annurev.cellbio.23.090506.123406>
5. Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. *Int J Physiol Pathophysiol Pharmacol.* 2011;3(2):140-155.
6. Creemers EE, Tijssen AJ, Pinto YM. Circulating MicroRNAs: Novel Biomarkers and Extracellular Communicators in Cardiovascular Disease? *Circ Res.* 2012;110(3):483-495. DOI: 10.1161/CIRCRESAHA.111.247452
7. Carella AM, Benvenuto A, Marinelli T, Melfitano A, Modola G, et al. Circulating Micro RNAs as Novel Disease Biomarkers: Can they be Applied in Daily Clinical Practice? An Update. *Current Topics in Medicine and Medical Research.* 2020;1(9):99-109. Print ISBN: 978-93-90149-59-9, eBook ISBN: 978-93-90149-05-6. DOI: 10.9734/bpi/ctmamr/v1
8. Geekiyanage H, Jicha GA, Nelson PT, Chan C. Blood serum miRNA: Non-invasive biomarkers for Alzheimer's disease. *Exp Neurol.* 2012;235(2):491-496. DOI: 10.1016/j.expneurol.2011.11.026
9. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, et al. Exosome mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 2007;9(6):654-659. DOI: 10.1038/ncb1596.
10. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. *Proc Natl Acad Sci U S A.* 2011;108(12):5003-5008. DOI: 10.1073/pnas.1019055108
11. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high density lipoproteins. *Nat Cell Biol.* 2011;13(4):423-433. DOI: 10.1038/ncb2210
12. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. Real-time quantification of microRNAs by stem-loop RT-PCR. *Nucleic Acids Res.* 2005;33(20):e179-e179. Available:<https://doi.org/10.1093/nar/gni178>

13. Valoczi A, Hornyik C, Varga N, Burgyan J, Kauppinen S, et al. Sensitive and specific detection of microRNAs by northern blot analysis using LNA modified oligonucleotide probes. *Nucleic Acids Res.* 2004;32(22):e175-e183.  
DOI: 10.1093/nar/gnh171
14. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, et al. MicroRNA expression profiles classify human cancers. *Nature.* 2005;435(7043):834-838.  
DOI: 10.1038/nature03702
15. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, et al. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. *PLoS One.* 2010;5(10):e13735.  
Available:<https://doi.org/10.1371/journal.pone.0013735>
16. Wu Q, Lu Z, Li H, Lu J, Guo L, et al. Next-generation sequencing of microRNAs for breast cancer detection. *J Biomed Biotechnol.* 2011;2011:597145.  
DOI: 10.1155/2011/597145
17. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. *Circ Cardiovasc Genet.* 2010;3(6):499-506.  
DOI: 10.1161/CIRCGENETICS.110.957415
18. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, et al. Plasma miR-208 as a biomarker of myocardial injury. *Clin Chem.* 2009;55(11):1944-1949.  
Available:<https://doi.org/10.1373/clinchem.2009.125310>
19. Bostjancic E, Zidar N, Stajer D, Glavac D. MicroRNAs miR-1, miR-133a, miR-133b and miR-208 are dysregulated in human myocardial infarction. *Cardiology.* 2010;115(3):163-169.  
DOI: 10.1159/000268088
20. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, et al. Circulating microRNA: A novel potential biomarker for early diagnosis of acute myocardial infarction in humans. *Eur Heart J.* 2010;31(6):659-666.  
DOI: 10.1093/eurheartj/ehq013
21. Wu AH, Feng YJ. Biochemical differences between cTnT and cTnl and their significance for diagnosis of acute coronary syndromes. *Eur Heart J.* 1998;19(SN):N25-29.
22. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, et al. Circulating microRNAs in patients with coronary artery disease. *Circ Res.* 2010;107(5):677-684.  
DOI: 10.1161/CIRCRESAHA.109.215566
23. Giral H, Kratzer A, Landmesser U. MicroRNAs in lipid metabolism and atherosclerosis. *Best Pract Res Clin Endocrinol Metab.* 2016;30(5):665-676.  
DOI: 10.1016/j.beem.2016.11.010
24. Welten SM, Goossens EA, Quax PH, Nossent AY. The multifactorial nature of microRNAs in vascular remodelling. *Cardiovasc Res.* 2016;110(1):6-22.  
Available:<https://doi.org/10.1093/cvr/cvw039>
25. Carella AM, Benvenuto A, Marinelli T, Melfitano A, Modola G, et al. Circulating MicroRNAs as Novel Disease Biomarkers: Can They be Applied in Daily Clinical Practice? *J Mol Genet Med.* 2017;11(1):1000241.  
DOI: 10.4172/1747-0862.1000241
26. Assmann TS, Recamonde-Mendoza M, De Souza BM, Crispim D. MicroRNA expression profiles and type 1 diabetes mellitus: systematic review and bioinformatic analysis. *Endocr Connect.* 2017;6(8):773-790.  
DOI: 10.1530/EC-17-0248
27. Osipova J, Fischer DC, Dangwal S, Volkmann I, Widera C, et al. Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. *J Clin Endocrinol Metab.* 2014;99(9):E1661-E1665.  
Available:<https://doi.org/10.1210/jc.2013-3868>
28. Harvey SJ, Jarad G, Cunningham J, Goldberg S, Schermer B, et al. Podocyte-specific deletion of dicer alters cytoskeletal dynamics and causes glomerular disease. *J Am Soc Nephrol.* 2008;19(11):2150-2158.  
DOI: 10.1681/ASN.2008020233
29. Wang S, Aurora AB, Johnson BA, Qi X, McAnally J, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. *Dev Cell.* 2008;15(2):261-271.  
DOI: 10.1016/j.devcel.2008.07.002

30. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, et al. miR-126 regulates angiogenic signaling and vascular integrity. *Dev Cell*. 2008;15(2):272-284.  
DOI: 10.1016/j.devcel.2008.07.008
31. Barutta F, Bruno G, Matullo G, Chaturvedi N, Grimaldi S, et al. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. *Acta Diabetol*. 2017;54(2):133-139.  
DOI: 10.1007/s00592-016-0915-4
32. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. *Nature*. 2008;456(7224):980-984.  
DOI: 10.1038/nature07511
33. Chau BN, Xin C, Hartner J, Ren S, Castano AP, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. *Sci Transl Med*. 2012;4(121):121ra18.  
DOI: 10.1126/scitranslmed.3003205
34. Kumarswamy R, Volkman I, Jazbutyte V, Dangwal S, Park DH, et al. Transforming growth factor- $\beta$ -induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. *Arterioscler Thromb Vasc Biol*. 2012;32(2):361-369.  
DOI: 10.1161/ATVBAHA.111.234286
35. Greco S, Fasanaro P, Castelvechio S, D'Alessandra Y, Arcelli D, et al. MicroRNA Dysregulation in Diabetic Ischemic Heart Failure Patients. *Diabetes*. 2012;61(6):1633-1641.  
Available:<https://doi.org/10.2337/db11-0952>
36. Magenta A, Greco S, Gaetano C, Martelli F. Oxidative stress and microRNAs in vascular diseases. *Int J Mol Sci*. 2013;14(9):17319-17346.  
Available:<https://doi.org/10.3390/ijms140917319>
37. Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. *Proc Natl Acad Sci USA*. 2009;106(14):5813-5818.  
DOI: 10.1073/pnas.0810550106
38. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. A pancreatic islet-specific microRNA regulates insulin secretion. *Nature*. 2004;432(7014):226-230.  
DOI: 10.1038/nature03076
39. Salunkhe VA, Esguerra JLS, Ofori JK, Mollet IG, Braun M, et al. Modulation of microRNA-375 expression alters voltage-gated Na<sup>+</sup> channel properties and exocytosis in insulin-secreting cells. *Acta Physiol*. 2015;213(4):882-892.  
Available:<https://doi.org/10.1111/alpha.12460>
40. Marchand L, Jalabert A, Meugnier E, Van den Hende K, Fabien N, et al. miRNA-375 a Sensor of Glucotoxicity Is Altered in the Serum of Children with Newly Diagnosed Type 1 Diabetes. *J Diabetes Res*. 2016;1869082.  
Available:<https://doi.org/10.1155/2016/1869082>
41. Lotte B, Nielsen LB, Wang C, Sørensen K, Bang-Berthelsen, et al. Circulating Levels of MicroRNA from Children with Newly Diagnosed Type 1 Diabetes and Healthy Controls: Evidence That miR-25 Associates to Residual Beta-Cell Function and Glycaemic Control during Disease Progression. *Exp Diabetes Res*. 2012;2012:896362.  
DOI: 10.1155/2012/896362
42. Samandari N, Mirza AH, Nielsen LB, Kaur S, Hougaard P, et al. Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus. *Diabetologia*. 2017;60(2):354-363.  
DOI: 10.1007/s00125-016-4156-4
43. Yang M, Ye L, Wang B, Gao J, Liu R, et al. Decreased miR-146 expression in peripheral blood mononuclear cells is correlated with ongoing islet autoimmunity in type 1 diabetes patients. *J Diabetes*. 2015;7(2):158-165.  
DOI: 10.1111/1753-0407.12163
44. Abuhatzira L, Xu H, Tahhan G, Boulougoura A, Schaffer AA, et al. Multiple microRNAs within the 14q32 cluster target the mRNAs of major type 1 diabetes autoantigens IA-2, IA-2beta, and GAD65. *FASEB J*. 2015;29(10):4374-4383.  
DOI: 10.1096/fj.15-273649
45. Zhang T, Li L, Shang Q, Lv C, Wang C, et al. Circulating miR-126 is a potential biomarker to predict the onset of type 2 diabetes mellitus in susceptible individuals. *Biochem Biophys Res Commun*. 2015;463(1-2):60-63.

- DOI: 10.1016/j.bbrc.2015.05.017
46. Liu Y, Gao G, Yang C, Zhou K, Shen B, et al. The role of circulating microRNA-126 (miR-126): a novel biomarker for screening prediabetes and newly diagnosed type 2 diabetes mellitus. *Int J Mol Sci.* 2014;15(6):10567-10577.  
DOI: 10.3390/ijms150610567
47. Al-Kafaji G, Al-Mahroos G, Abdulla Al-Muhtaresh H, Sabry MA, Abdul Razzak R, et al. Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients. *Biomarkers.* 2017;22(3-4):268-278.  
DOI: 10.1080/1354750X.2016.1204004
48. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. *Circ Res.* 2010;107(6):810-817.  
DOI: 10.1161/CIRCRESAHA.110.226357
49. Witkowski M, Weithauser A, Tabaraie T, Steffens D, Kränkel N, et al. Micro-RNA-126 Reduces the Blood Thrombogenicity in Diabetes Mellitus via Targeting of Tissue Factor. *Arterioscler Thromb Vasc Biol.* 2016;36(6):1263-1271.  
DOI: 10.1161/ATVBAHA.115.306094
50. Willeit P, Skrobilin P, Moschen AR, Yin X, Kaudewitz D, et al. Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes. *Diabetes.* 2017;66(2):347-357.  
DOI: 10.2337/db16-0731
51. Wan S, Wang J, Wang J, Wu J, Song J, et al. Increased serum miR-7 is a promising biomarker for type 2 diabetes mellitus and its microvascular complications. *Diabetes Res Clin Pract.* 2017;130:171-179.  
DOI: 10.1016/j.diabres.2017.06.005
52. Lv C, Zhou YH, Wu C, Shao Y, Lu CL, et al. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy. *Diabetes Metab Res Rev.* 2015;31(7):717-724.  
DOI: 10.1002/dmrr.2659
53. Chien HY, Chen CY, Chiu YH, Lin YC, Li WC. Differential microRNA Profiles Predict Diabetic Nephropathy Progression in Taiwan. *Int J Med Sci.* 2016;1(13):457-465.  
DOI: 10.7150/ijms.15548
54. Carella AM, Marinelli T, Melfitano A, Di Pumpo M, Modola G, et al. Circulating Micro-RNAs in Diabetic Patients: What Meaning? Short Review. *Diabetes Obes Int J.* 2018;3(1):000171.  
DOI: 10.23880/DOIJ-16000171
55. Jaeger A, Zollinger L, Saely CH, Muendlein A, Evangelakos I, et al. Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. *Sci Rep.* 2018;8(1):14274.  
DOI: 10.1038/s41598-018-32274-9
56. Ghorbani S, Mahdavi R, Alipoor B, Panahi G, Nasli Esfahani E, et al. Decreased serum microRNA-21 level is associated with obesity in healthy and type 2 diabetic subjects. *Arch Physiol Biochem.* 2018;124(4):300-305.  
DOI: 10.1080/13813455.2017.1396349
57. Monfared YK, Honardoost M, Sarookhani MR, Farzam SA. Circulating miR-135 May Serve as a Novel Co-biomarker of HbA1c in Type 2 Diabetes. *Appl Biochem Biotechnol.* 2020;191(2):623-630.  
DOI:10.1007/s12010-019-03163-2
58. Cui X, You L, Zhu L, Wang X, Zhou Y, et al. Change in circulating microRNA profile of obese children indicates future risk of adult diabetes. *Metabolism.* 2018;78:95-105.  
DOI: 10.1016/j.metabol.2017.09.006
59. García-Jacobo RE, Uresti-Rivera EE, Portales-Pérez DP, González-Amaro R, Lara-Ramírez EE, et al. Circulating miR-146a, miR-34a and miR-375 in type 2 diabetes patients, pre-diabetic and normal-glycaemic individuals in relation to  $\beta$ -cell function, insulin resistance and metabolic parameters. *Clin Exp Pharmacol Physiol.* 2019;46(12):1092-1100.  
DOI: 10.1111/1440-1681.13147
60. Cheng L, Zhou M, Zhang D, Chen B. Association of miR-146a polymorphism rs2910164 and type 2 diabetes risk: a meta-analysis. *J Int Med Res.* 2020;48(8):300060520931313.

- DOI: 10.1177/0300060520931313
61. Margaritis K, Margioulas-Siarkou G, Margioulas-Siarkou C, Petousis S, Kotanidou EP, et al. Circulating serum and plasma levels of micro-RNA in type-1 diabetes in children and adolescents: A systematic review and meta-analysis. *Eur J Clin Invest.* 2021;e13510.  
DOI: 10.1111/eci.13510
  62. Satake E, Pezzolesi MG, Md Dom ZI, Smiles AM, Niewczas MA, et al. Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. *Diabetes.* 2018;67(5):1013-1023.  
DOI: 10.2337/db17-1207
  63. Snowwhite I, Pastori R, Sosenko J, Messinger Cayetano S, Pugliese A. Baseline Assessment of circulating MicroRNAs Near Diagnosis of Type 1 Diabetes Predicts Future Stimulated Insulin Secretion. *Diabetes.* 2021;70(2):638-651.  
DOI: 10.2337/db20-0817
  64. Santos AS, Cunha Neto E, Fukui RT, Ferreira LRP, Silva MER. Increased Expression of Circulating microRNA 101-3p in Type 1 Diabetes Patients: New Insights Into miRNA-Regulated Pathophysiological Pathways for Type 1 Diabetes. *Front Immunol.* 2019;10:1637.  
DOI: 10.3389/fimmu.2019.01637
  65. Yoffe L, Polsky A, Gilam A, Raff C, Mecacci F, et al. Early diagnosis of gestational diabetes mellitus using circulating microRNAs. *Eur J Endocrinol.* 2019;181(5):565-577.  
DOI: 10.1530/EJE-19-0206
  66. Abdeltawab A, Zaki ME, Abdeldayem Y, Mohamed AA, Zaied SM. Circulating micro RNA-223 and angiopoietin-like protein 8 as biomarkers of gestational diabetes mellitus. *Br J Biomed Sci.* 2021;78(1):12-17.  
DOI: 10.1080/09674845.2020.1764211
  67. Hocaoglu M, Demirer S, Senturk H, Turgut A, Komurcu-Bayrak E. Differential expression of candidate circulating microRNAs in maternal blood leukocytes of the patients with preeclampsia and gestational diabetes mellitus. *Pregnancy Hypertens.* 2019;17:5-11.  
DOI: 10.1016/j.preghy.2019.04.004
  68. Gillet V, Ouellet A, Stepanov Y, Rodosthenous RS, Croft EK, et al. miRNA Profiles in Extracellular Vesicles From Serum Early in Pregnancies Complicated by Gestational Diabetes Mellitus. *J Clin Endocrinol Metab.* 2019;104(11):5157-5169.  
DOI: 10.1210/jc.2018-02693
  69. Amr KS, Abdelmawgoud H, Ali ZY, Shehata S, Raslan HM. Potential value of circulating microRNA-126 and microRNA-210 as biomarkers for type 2 diabetes with coronary artery disease. *Br J Biomed Sci.* 2018;75(2):82-87.  
DOI: 10.1080/09674845.2017.1402404
  70. Yuan Y, Peng W, Liu Y, Xu Z. Circulating miR-130 and its target PPAR- $\gamma$  may be potential biomarkers in patients of coronary artery disease with type 2 diabetes mellitus. *Mol Genet Genomic Med.* 2019;7(9):e909.  
DOI: 10.1002/mgg3.909
  71. Luo M, Wang G, Xu C, Zeng M, Lin F, et al. Circulating miR-30c as a predictive biomarker of type 2 diabetes mellitus with coronary heart disease by regulating PAI-1/VN interactions. *Life Sci.* 2019;239:117092.  
DOI: 10.1016/j.lfs.2019.117092
  72. Wang W, Li Z, Zheng Y, Yan M, Cui Y, et al. Circulating microRNA-92a level predicts acute coronary syndrome in diabetic patients with coronary heart disease. *Lipids Health Dis.* 2019;18(1):22.  
DOI: 10.1186/s12944-019-0964-0
  73. Wang R, Ding YD, Gao W, Pei YQ, Yang JX, et al. Serum microRNA-204 levels are associated with long-term cardiovascular disease risk based on the Framingham risk score in patients with type 2 diabetes: results from an observational study. *J Geriatr Cardiol.* 2020;17(6):330-337.  
DOI: 10.11909/j.issn.1671-5411.2020.06.006
  74. Giordano M, Trotta MC, Ciarambino T, D'Amico M, Galdiero M, et al. Circulating MiRNA-195-5p and -451a in Diabetic Patients with Transient and Acute Ischemic Stroke in the Emergency Department. *Int J Mol Sci.* 2020;21(20):7615.  
DOI: 10.3390/ijms21207615

75. Eroglu İ, Korkmaz H, Ozturk KH, Sirin FB, Sevik S, et al. New risk factors in diabetic nephropathy: microRNA-196-3p and microRNA-203. *Minerva Endocrinol*; 2020.  
DOI: 10.23736/S0391-1977.20.03204-6
76. Ren H, Wu C, Shao Y, Liu S, Zhou Y, et al. Correlation between serum miR-154-5p and urinary albumin excretion rates in patients with type 2 diabetes mellitus: a cross-sectional cohort study. *Front Med*. 2020;14(5):642-650.  
DOI: 10.1007/s11684-019-0719-3
77. Akhbari M, Khalili M, Shahrabi-Farahani M, Biglari A, Bandarian F. Expression Level of Circulating Cell Free miR-155 Gene in Serum of Patients with Diabetic Nephropathy. *Clin Lab*. 2019;65(8).  
DOI: 10.7754/Clin.Lab.2019.190209
78. Kim H, Bae YU, Jeon JS, Noh H, Park HK, et al. The circulating exosomal microRNAs related to albuminuria in patients with diabetic nephropathy. *J Transl Med*. 2019;17(1):236.  
DOI: 10.1186/s12967-019-1983-3
79. Sangalli E, Tagliabue E, Sala L, Prattichizzo F, Uccellatore A, et al. Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. *Front Endocrinol (Lausanne)*. 2020;11:254.  
DOI: 10.3389/fendo.2020.00254
80. Greco M, Chiefari E, Accattato F, Corigliano DM, Arcidiacono B, et al. MicroRNA-1281 as a Novel Circulating Biomarker in Patients With Diabetic Retinopathy. *Front Endocrinol (Lausanne)*. 2020;11:528.  
DOI: 10.3389/fendo.2020.00528
81. Yang Y, Liu Y, Li Y, Chen Z, Xiong Y, et al. MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy. *J Clin Endocrinol Metab*. 2020;105(11):3404-15.  
DOI: 10.1210/clinem/dgaa538
82. Ji H, Yi Q, Chen L, Wong L, Liu Y, et al. Circulating miR-3197 and miR-2116-5p as novel biomarkers for diabetic retinopathy. *Clin Chim Acta*. 2020;501:147-153.  
DOI: 10.1016/j.cca.2019.10.036
83. Li JY, Cheng B, Wang XF, Wang ZJ, Zhang HM, et al. Circulating MicroRNA-4739 May Be a Potential Biomarker of Critical Limb Ischemia in Patients with Diabetes. *Biomed Res Int*. 2018;2018:4232794.  
DOI: 10.1155/2018/4232794
84. Spinetti G, Sangalli E, Tagliabue E, Maselli D, Colpani O, et al. MicroRNA-21/PDCD4 Proapoptotic Signaling From Circulating CD34+ Cells to Vascular Endothelial Cells: A Potential Contributor to Adverse Cardiovascular Outcomes in Patients With Critical Limb Ischemia. *Diabetes Care*. 2020;43(7):1520-1529.  
DOI: 10.2337/dc19-2227
85. Cheng B, Li JY, Li XC, Wang XF, Wang ZJ, et al. MiR-323b-5p acts as a novel diagnostic biomarker for critical limb ischemia in type 2 diabetic patients. *Sci Rep*. 2018;8(1):15080.  
DOI: 10.1038/s41598-018-33310-4
86. Pasquier J, Ramachandran V, Abu-Qaoud MR, Thomas B, Benurwar MJ, et al. Differentially expressed circulating microRNAs in the development of acute diabetic Charcot foot. *Epigenomics*. 2018;10(10):1267-1278.  
DOI: 10.2217/epi-2018-0052
87. Thibonnier M, Esau C. Metabolic Benefits of MicroRNA-22 Inhibition. *Nucleic Acid Ther*. 2020;30(2):104-116.  
DOI: 10.1089/nat.2019.0820
88. Ye D, Zhang T, Lou G, Xu W, Dong F, et al. Plasma miR-17, miR-20a, miR-20b and miR-122 as potential biomarkers for diagnosis of NAFLD in type 2 diabetes mellitus patients. *Life Sci*. 2018;208:201-207.  
DOI: 10.1016/j.lfs.2018.07.029
89. Deng X, Qin S, Chen Y, Liu HY, Yuan E, et al. B-RCA revealed circulating miR-33a/b associates with serum cholesterol in type 2 diabetes patients at high risk of ASCVD. *Diabetes Res Clin Pract*. 2018;140:191-199.  
DOI: 10.1016/j.diabres.2018.03.024

90. Li P, Fan C, Cai Y, Fang S, Zeng Y, et al. Transplantation of brown adipose tissue up-regulates miR-99a to ameliorate liver metabolic disorders in diabetic mice by targeting NOX4. *Adipocyte*. 2020;9(1):57-67.  
DOI: 10.1080/21623945.2020.1721970
91. Price NL, Ramirez CM, Fernández-Hernando C. Relevance of microRNA in metabolic diseases. *Crit Rev Clin Lab Sci*. 2014;51(6):305-320.

**Biography of author(s)**



**Carella Angelo Michele**

Department of Internal Medicine, "T. Masselli-Mascia" Hospital, San Severo, Italy.

After graduating in Medicine, he obtained specialization in Internal Medicine, attended postgraduate courses on Diabetes and Obesity and obtained second-level university Master's Degree in Healthcare Management.

He operates in the "Internal Medicine Department" (currently "Medical Semi-Intensive COVID Area) of "T. Masselli - Mascia" Hospital in San Severo (Foggia), Italy.

He is a Past teacher at Medical Faculty of Foggia University, degree course in Health Professions, he took part as researcher/co-researcher in some clinical studies, published in international journals, as DAVID Study, ESPORT Study, ATA-AF Study and DIAMOND Study.

He is Editorial Board Member and Reviewer of a lot of scientific journals and he is Author of several scientific publications (h-index 6, according to Google Scholar citation search).

He took part, as a speaker, in national and international scientific congresses and meetings and he is member of scientific societies as "Italian Association of Diabetes specialists" (affiliated with IDF), "Italian Association of Dietetics and clinical nutrition", "Italian Federation of Hospital Internists Associations"; moreover he is member of "Diabetes and Cardiovascular Disease Study Group", official study group of EASD.

His research areas and field of expertise include Internal Medicine; Diabetology; Obesity and its complications, Nutrition and Metabolism.

Website: A.M. Carella is registered on Google Scholar, Publons, Research Gate and ORCID (ORCID iD: 0000-0003-4825-9620).

---

© Copyright (2021): Author(s). The licensee is the publisher (B P International).

**DISCLAIMER**

This chapter is an extended version of the article published by the same author(s) in the following journal. Diabetes and Obesity International Journal, 3(1): 000171, 2018.